$815.7 K

CAPS Mkt cap, 23-Oct-2020
Capstone Therapeutics Net income (Q2, 2019)-668 K
Capstone Therapeutics EBIT (Q2, 2019)-605 K
Capstone Therapeutics Cash, 30-Jun-2019305 K

Capstone Therapeutics Income Statement

Annual

USDFY, 2011FY, 2012FY, 2018

Revenue

(2.0m)

R&D expense

6.4m9.0k52.0k

General and administrative expense

3.5m1.8m554.0k

Operating expense total

9.9m1.8m606.0k

EBIT

9.7m(4.1m)

Interest income

31.0k96.0k

Pre tax profit

9.9m(4.1m)432.0k

Income tax expense

158.0k52.0k

Net Income

9.7m(3.6m)

Capstone Therapeutics Balance Sheet

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

19.6m17.6m13.1m12.8m11.4m9.2m8.1m7.2m5.5m4.2m3.1m1.5m1.0m637.0k718.0k692.0k1.1m486.0k437.0k1.7m805.0k2.3m1.8m1.1m305.0k

Prepaid Expenses

532.0k200.0k330.0k305.0k197.0k83.0k235.0k345.0k277.0k631.0k509.0k360.0k225.0k77.0k78.0k82.0k47.0k84.0k76.0k11.0k68.0k129.0k398.0k

Current Assets

19.8m17.8m13.6m13.0m11.7m9.5m8.3m7.3m5.7m4.5m3.4m2.2m1.5m997.0k943.0k769.0k1.2m568.0k484.0k1.8m881.0k2.3m1.9m1.2m703.0k

PP&E

214.0k187.0k136.0k34.0k28.0k13.0k7.0k5.0k2.0k

Total Assets

20.0m18.0m13.8m13.1m12.7m10.5m9.2m8.1m6.5m5.3m4.1m2.8m2.1m1.5m1.4m1.2m1.6m882.0k758.0k2.0m1.0m2.4m2.0m1.2m703.0k

Accounts Payable

385.0k337.0k144.0k81.0k209.0k313.0k74.0k200.0k253.0k112.0k225.0k185.0k211.0k132.0k173.0k402.0k325.0k324.0k393.0k157.0k203.0k244.0k415.0k630.0k797.0k

Current Liabilities

1.2m764.0k156.0k93.0k214.0k334.0k101.0k206.0k288.0k430.0k471.0k365.0k351.0k188.0k266.0k431.0k369.0k391.0k1.5m193.0k206.0k247.0k417.0k732.0k819.0k

Long-term debt

2.2m

Total Debt

2.2m

Common Stock

20.0k20.0k20.0k20.0k20.0k20.0k20.0k20.0k20.0k20.0k20.0k20.0k20.0k20.0k20.0k20.0k20.0k20.0k20.0k27.0k27.0k27.0k27.0k27.0k27.0k

Additional Paid-in Capital

189.0m189.0m189.1m189.2m189.2m189.2m189.2m189.2m189.2m189.3m189.3m189.3m189.4m189.4m189.5m189.5m189.5m189.5m189.5m190.5m190.5m190.5m190.5m190.5m190.5m

Retained Earnings

(170.2m)(171.8m)(175.5m)(176.2m)(177.2m)(179.1m)(180.1m)(181.3m)(183.0m)(184.4m)(185.7m)(186.9m)(187.7m)(188.1m)(189.3m)(189.7m)(189.3m)(190.0m)(190.2m)(190.8m)(192.0m)(190.7m)(191.4m)(192.6m)(193.3m)

Total Equity

18.8m17.2m13.6m13.0m12.5m10.1m9.1m7.9m6.2m4.9m3.6m2.4m1.8m1.4m147.0k(231.0k)228.0k(509.0k)(715.0k)(315.0k)(1.5m)(182.0k)(870.0k)(2.1m)(2.8m)

Debt to Equity Ratio

-6.9 x

Debt to Assets Ratio

1.1 x

Financial Leverage

1.1 x1 x1 x1 x1 x1 x1 x1 x1 x1.1 x1.1 x1.2 x1.2 x1.1 x9.6 x-5.2 x7 x-1.7 x-1.1 x-6.5 x-0.7 x-13.3 x-2.3 x-0.6 x-0.3 x

Capstone Therapeutics Cash Flow

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

9.7m(3.6m)(4.1m)(4.2m)(2.8m)(663.0k)(1.8m)

Depreciation and Amortization

117.0k29.0k173.0k160.0k157.0k179.0k205.0k157.0k

Accounts Payable

(169.0k)156.0k(145.0k)36.0k130.0k(5.0k)(52.0k)48.0k

Cash From Operating Activities

(10.6m)(3.4m)(4.0m)(4.1m)(2.2m)(1.2m)(1.6m)66.0k

Purchases of PP&E

(19.0k)

Cash From Investing Activities

(19.0k)(206.0k)4.0k

Cash From Financing Activities

1.0m946.0k2.1m

Net Change in Cash

(10.6m)(3.6m)(3.9m)(4.1m)(1.2m)(263.0k)577.0k66.0k

Income Taxes Paid

Capstone Therapeutics Ratios

USDQ2, 2011

Financial Leverage

1.1 x